20 July 2023
SHARE NOW
ATW
Cell Therapy
Clinical Trials
Gene Therapy
GMP
Strategy
This full session from Advanced Therapies Week 2023 includes presentations dedicated to pioneering a new wave of gene-agnostic gene therapy, and critical technological advancements driving robust development, manufacturing and testing.
After an introduction from Matthew Hewitt, Executive Director Scientific Services, Cell and Gene Therapy at Charles River Laboratories, two presentations followed before a closing panel with a Q&A.
Presentation 1: Pioneering a New Wave of Gene-Agnostic Gene Therapy with Samarendra Mohanty, Co-Founder and President, Nanoscope Therapeutics
- Recent advancements in gene therapy
- Overview of retinal degenerative disease
- Novel, gene-agnostic optogenetics approach to treat retinal degenerative disease
- Clinical program overview and next steps
Presentation: Present and Future of Cell and Gene Therapies with Robert Keefe, Chief Development Officer, BlueSphere Bio
- Overview of cell therapy progress to date
- Critical technological advancements driving robust development, manufacturing and testing
- Leveraging a discovery platform to engineer a TCR-T cell therapy product to treat AML
- Future direction of the cell therapy industry
This Session was presented at Advanced Therapies Week 2023, in partnership with Charles River.
More like this
Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment
Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023
Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux
Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023
The Cell & Gene Therapy Manufacturing Capacity Map
The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023
